SCHEMBL25830865

SCHEMBL25830865

CC(C)NCCOCCOCCCNC(=O)C(C)C

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
KDM4E B2RXH2 5/20 0.41
POLB P06746 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2C9 P11712 1/20 0.41
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 3/20 0.38
TSHR P16473 2/20 0.38
HPGD P15428 2/20 0.36
GAA P10253 1/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24673728 1.00 KMT2A (0.51) KMT2AMEN1KDM4EPOLBTDP1
SCHEMBL25830878 0.98 KMT2A (0.49) KMT2AMEN1KDM4EPOLBTDP1
SCHEMBL23807051 0.94 KMT2A (0.49) KMT2AMEN1KDM4EPOLBTDP1
SCHEMBL24764568 0.94 KMT2A (0.45) KMT2AMEN1KDM4EPOLBTDP1
SCHEMBL21105779 0.93 KMT2A (0.46) KMT2AMEN1KDM4ETDP1CYP2D6
SCHEMBL21106165 0.91 KMT2A (0.61) KMT2AMEN1KDM4EPOLBTDP1
SCHEMBL18908759 0.91 KMT2A (0.61) KMT2AMEN1KDM4EPOLBTDP1
SCHEMBL21106234 0.91 KMT2A (0.61) KMT2AMEN1KDM4EPOLBTDP1
SCHEMBL18908752 0.91 KMT2A (0.61) KMT2AMEN1KDM4EPOLBTDP1
SCHEMBL25834730 0.91 KMT2A (0.61) KMT2AMEN1KDM4EPOLBTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KMT2A 445/4885MEN1 4055/4885KDM4E 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.